![](https://kimberlylab.massgeneral.org/wp-content/uploads/2017/01/CHARM-logo-cropped-e1569179372511.jpg)
Our primary focus in clinical trials is the prevention of cerebral edema, testing the hypothesis that the sulfonylurea receptor 1 (Sur1) mediates edema formation after stroke. The clinical development of the Sur1 inhibitor, intravenous glyburide, began with a Phase 2a pilot clinical trial (GAMES-Pilot Trial), which evaluated the safety and efficacy for the prevention of […]